

Prevention of severe RSV disease in babies

RSV (respiratory syncytial virus) is the most common cause of respiratory infections leading to infant hospitalization. We offer an antibody developed against the RS virus called nirsevimab in our hospitals to infants and children who are at risk of severe RSV infection.

The aim of nirsevimab is to prevent the majority of severe illnesses and infant hospitalizations caused by RSV. Immunization with nirsevimab is voluntary and free of charge for families.

Nirsevimab is offered to

- All children born after August 1, 2024
- Infants born at HUS maternity hospitals from October 23, 2024
- Children under the age of 12 months who are at risk for a severe RSV disease at HUS New Children's Hospital, Jorvi Hospital, and Hyvinkää Hospital from November 1, 2024.


The City of Helsinki and the wellbeing services counties of Uusimaa are responsible for administering nirsevimab according to their guidelines to healthy children born between August 1 – October 22, 2024.

Information for risk groups

Nirsevimab is given in November to children under the age of one year who are at risk for severe disease. This is done before the start of the epidemic. The appointment booking will open on October 28, 2024.

At-risk groups:

- Born before gestational age of 29+0 weeks
- Born at gestational age between 29+0 and 36+6 weeks and the family has another child under the age of 6
- Heart defect or heart disease for which surgery is planned or regular medication is needed.
- Severe immunodeficiency according to the attending physician
- Lung disease in a premature infant, i.e. bronchopulmonary dysplasia, for which some form of respiratory support treatment has been needed in the past 6 months or similar severe chronic pulmonary disease
- Down syndrome



More information: hus.fi/en/rsv